Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
- PMID: 8710899
- PMCID: PMC38701
- DOI: 10.1073/pnas.93.16.8502
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
Abstract
The development of new capillary networks from the normal microvasculature of the host appears to be required for growth of solid tumors. Tumor cells influence this process by producing both inhibitors and positive effectors of angiogenesis. Among the latter, the vascular endothelial growth factor (VEGF) has assumed prime candidacy as a major positive physiological effector. Here, we have directly tested this hypothesis in the brain tumor, glioblastoma multiforme, one of the most highly vascularized human cancers. We introduced an antisense VEGF expression construct into glioblastoma cells and found that (i) VEGF mRNA and protein levels were markedly reduced, (ii) the modified cells did not secrete sufficient factors so as to be chemoattractive for primary human microvascular endothelial cells, (iii) the modified cells were not able to sustain tumor growth in immunodeficient animals, and (iv) the density of in vivo blood vessel formation was reduced in direct relation to the reduction of VEGF secretion and tumor formation. Moreover, revertant cells that recovered the ability to secrete VEGF regained each of these tumorigenic properties. These results suggest that VEGF plays a major angiogenic role in glioblastoma.
Similar articles
-
Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.Oncogene. 1999 Aug 26;18(34):4860-9. doi: 10.1038/sj.onc.1202869. Oncogene. 1999. PMID: 10490819
-
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.Am J Pathol. 1997 Dec;151(6):1523-30. Am J Pathol. 1997. PMID: 9403702 Free PMC article.
-
Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.Cancer Res. 1998 Sep 15;58(18):4185-92. Cancer Res. 1998. PMID: 9751633
-
[Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 Mar;34(2):165-70. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002. PMID: 12006990 Chinese.
-
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Jpn J Cancer Res. 1996 Sep;87(9):963-71. doi: 10.1111/j.1349-7006.1996.tb02127.x. Jpn J Cancer Res. 1996. PMID: 8878460 Free PMC article.
Cited by
-
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.Neoplasia. 1999 Apr;1(1):31-41. doi: 10.1038/sj.neo.7900006. Neoplasia. 1999. PMID: 10935468 Free PMC article.
-
Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens.Mod Pathol. 2023 Jan;36(1):100034. doi: 10.1016/j.modpat.2022.100034. Mod Pathol. 2023. PMID: 36788070 Free PMC article.
-
VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.J Exp Ther Oncol. 2008;7(2):89-97. J Exp Ther Oncol. 2008. PMID: 18771083 Free PMC article.
-
Steady-state analysis of genetic regulatory networks modelled by probabilistic boolean networks.Comp Funct Genomics. 2003;4(6):601-8. doi: 10.1002/cfg.342. Comp Funct Genomics. 2003. PMID: 18629023 Free PMC article.
-
The emerging role of anti-angiogenic therapy for malignant glioma.Curr Treat Options Oncol. 2008 Feb;9(1):1-22. doi: 10.1007/s11864-008-0052-6. Epub 2008 Feb 7. Curr Treat Options Oncol. 2008. PMID: 18256938 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources